The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
FDA Action Alert: Bristol Myers Squibb/Juno, Seattle Genetics, BioMarin and Tricida
Adeno-Associated Virus (AAV), B Cell Lymphomas, Biologics License Application (BLA), Brain Metastases, CAR-T Therapy, Chronic Kidney Disease, Diffuse large B-cell lymphoma (DLBCL), FDA, FDA/Regulatory, Hemophilia A, HER2-positive breast cancer, Immunotherapy, New Drug Applicationa, Project Orbis, Quarterly results, T-CellsThe U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
Verastem signed a definitive deal to sell the company’s global commercial and development rights for Copiktra (duvelisib) to Secura Bio.
The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) in combination with Rituxan (rituximab) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who are new to therapy.
The U.S. Food and Drug Administration granted orphan drug designation to AFM13, Affimed N.V.’s lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.
For nearly 30 years, Richard Miller has been at the forefront of developing treatments for lymphomas, most notably the multi-billion dollar breakthroughs Rituxan and Imbruvica. In recognition of his decades of work, Miller was awarded with the 2020 Drug Hunter Award.
ASH Roundup: Bristol-Myers Squibb, bluebird bio, Oryzon and More
Acute Myeloid Leukemia (AML), American Society of Hematology (ASH) Annual Meeting, Chronic Lymphocytic Leukemia (CLL), Clinical Data, Clinical Trials, Diffuse Large B-Cell Lymphoma (DLBCL), Epigenetic, LSD1, Myelodysplastic Syndromes, Progression-Free Survival (PFS), R&D, Relapse/Refractory Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), Small MoleculesHundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
Bristol-Myers and Celgene's Liso-Cel Hits Mark in Multiple Cancer Studies
American Society of Hematology (ASH) Annual Meeting, B-Cell Non-Hodgkin Lymphoma, Cancer, CAR-T Therapy, Chronic Lymphocytic Leukemia (CLL), Clinical Trials, Hematopoietic Stem Cell Transplantation (HSCT), Immune Cells, R&D, Small Lymphocytic Lymphoma (SLL)Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.
AstraZeneca shares rose 2.7 percent after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie.
Roche won the U.S. Food and Drug Administration’s breakthrough therapy tag for Gazyva in lupus nephritis, boosting the Swiss drugmaker’s efforts to recycle the 2013-approved lymphoma medicine for new indications.